Диссертация (1154764), страница 19
Текст из файла (страница 19)
– Р. 673–81.96. Cao, J.1. The prevalence, risk factors and prognosis of aspirin resistance in elderlymale patients with cardiovascular disease / J.1. Cao, L. Liu, L. Fan. et. al. // AgingMale. – 2012 – 15 (3). –Р. 140-147.97. Cayla, G. Platelet function monitoring to adjust antiplatelet therapy in elderly patientsstented for an acute coronary syndrome (ANTARCTIC): an open-label, blindedendpoint, randomised controlled superiority trial / G. Cayla, T. Cuisset, J.
Silvain //Lancet. – 2016. – 388(10055). – Р. 2015-22.98. Cattaneo, M. The clinical relevance of response variability to antiplatelet therapy /M. Cattaneo // Hematology Am Soc Hematol Educ Program. –2011. – Р. 70-75.99. Cattaneo, M. The role of laboratory monitoring in antiplatelet therapy / M. Cattaneo// Handb Exp Pharmacol. – 2012. – 210. – Р. 471-494.100. Chen, W.H. Prevalence, profile, predictors and natural history of aspirin resistancemeasured by the Ultegra Rapid Platelet Function Assay-ASA in patients with coronaryheart disease / W.H. Chen, X. Cheng, P.Y.
Lee et al. // Circulation. – 2005. – 111. –Р. 339.101. Christiaens, L.1. Monitoring of the antiplatelet drugs effect in patients withcoronary artery disease: what is the real clinical impact? / L.1. Christiaens, L. Macchi// Curr Vasc Pharmacol. – 2007. – 5(4). – Р. 293-301.102.Chu. S.G. Mean platelet volume as a predictor of cardiovascular risk: a systematicreview and meta-analysis / S.G. Chu, R.C, Becker, P.B. Berger // J Thromb Haemost.– 2010.
– 8(1). – Р. 148-156.103. Clappers, N. The C50T polymorphism of the cyclooxygenase-1 gene and the riskof thrombotic events during low-dose therapy with acetylsalicylic acid / N. Clappers,M.G. van Oijen, S. Sundaresan // Thromb Haemost. – 2008. – 100(1). – Р. 70-5.126104. Coccheri, S. Antiplatelet drugs - do we need new options? With a reappraisal ofdirect thromboxane inhibitors / S.
Coccheri // Drugs. – 2010. – 70(7). – Р. 887-908.105. Coccheri. S. Antiplatelet therapy: controversial aspects / S. Coccheri // ThrombRes. – 2012. – 129(3). – Р. 225-229.106. Crescente, M.1. Response variability to aspirin as assessed by the platelet functionanalyzer (PFA)-100. A systematic review / M.1. Crescente, A. Di Castelnuovo, L.Iacoviello // Thromb Haemost. – 2008. – 99(1). – Р. 14-26.107.Dobesh, P.P.
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel,Prasugrel, and Ticagrelor / P.P. Dobesh, S Varnado, M. Doyle // Curr Pharm – 2016.– 22(13). – Р. 1918-32.108. Dretzke, J. The prognostic utility of tests of platelet function for the detection of'aspirin resistance' in patients with established cardiovascular or cerebrovasculardisease: a systematic review and economic evaluation / J. Dretzke, R.D.
Riley, M.Lordkipanidzé et. al. // Health Technol Assess. – 2015. –19 (37). – Р. 1-366.109. Eikelboom, J.W. Antiplatelet Drugs: Antithrombotic Therapy and Prevention ofThrombosis, 9th ed: American College of Chest Physicians Evidence-Based ClinicalPractice Guidelines / J.W.
Eikelboom, J. Hirsh, F.A. Spencer et. al. // Chest. – 2012.– 141(2 Suppl). – Р. 89-119.110. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,2016. // http://www.escardio.org/guidelines.111. ESC Guidelines for the management of acute coronary syndromes in patientspresenting without persistent ST-segment elevation 2015 // European Heart Journal. –2016. – 37. – Р. 267-315112. European Guidelines on cardiovascular disease prevention in clinical practice(version 2012) // European Heart Journal.
– 2012. – 33. – Р.1635–1701113. Expert consensus document on the use of antiplatelet agents. The task force on theuse of antiplatelet agents in patients with atherosclerotic cardiovascular disease of theEuropean society of cardiology. European Society of Cardiology. // Eur Heart J. –2004. –25(2). – Р. 166-181.127114. Feher, G.
The genetics of antiplatelet drug resistance / G. Feher, A. Feher, G. Puschet al. // Clin Genet. – 2009. – 75(1). – P. 1-18.115. Foussas, S.G. The impact of aspirin resistance on the long-term cardiovascularmortality in patients with non-ST segment elevation acute coronary syndromes / SGFoussas, M.N. Zairis, V.G. Tsirimpis // Clin Cardiol. – 2009. – 32(3). – Р.
142-7.116. Freynhofer, M.K. Antiplatelet drugs in patients with enhanced platelet turnover:biomarkers versus platelet function testing / M.K Freynhofer., S.C. Gruber, E.L Grove// Thromb Haemost. – 2015. – 114(3). – Р. 459-68.117. Gazouli, M. Genetics in anti-platelet treatment / M. Gazouli // Curr Pharm Des. –2016. – 22(29). – Р. 4506-11.118. Grove, E.L. Antiplatelet effect of aspirin in patients with coronary artery disease /E.L.Grove // Dan Med J. – 2012. –59(9): – B4506.119.
Grove E.L. Antiplatelet therapy in acute coronary syndromes / E.L. Grove, M.Würtz, M.R. Thomas // Expert Opin Pharmacother. – 2015. – 16(14). – Р. 2133-47.120. Grove, E.L. Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactionswith Antiplatelet Drugs / E.L. Grove, M. Würtz //Adv Exp Med Biol. – 2017. – 906.– Р. 325-50.121.
Gurney, D. Platelet function testing: from routine to specialist testing / D. Gurney// Br J Biomed Sci. – 2016. – 73(1). – Р. 10-20.122. Harrison, P. Measuring antiplatelet drug effects in the laboratory / P Harrison, A.L.3rd Frelinger, M.I. Furman et al.
// Thromb Res. – 2007. –120(Р.3). – Р. 323-36.123. Hou, Y. Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogenindependent platelet aggregation and fibronectin-mediated protein wave of hemostasis/ Y.Hou, N. Carrim, Y. Wang // J Biomed Res. – 2015. – 30. – Р. 29.124. Ibrahim, O. Aspirin resistance in patients with acute coronary events: risk factorsand prevalence as determined by whole blood multiple electrode aggregometry / O.Ibrahim, O. Maskon, N.Darinah // Pak J Med Sci. – 2013. – 29(6). – Р. 1319-22.125. Israels, S.J. Laboratory testing for platelet function disorders / S.J. Israels // Int JLab Hematol.
– 2015. – 37 Suppl 1. – Р. 18-24.128126. John, J. You. Antithrombotic Therapy for Atrial Fibrillation: AntithromboticTherapy and Prevention of Thrombosis, 9th ed: American College of Chest PhysiciansEvidence-Based Clinical Practice Guidelines / J. You John, E. Singer Daniel, A.Patricia. et. al. // Chest. – 2012.
– 141(2 Suppl): – Р. 531S–575S.127. Kaplon-Cieslicka, A. Younger age, higher body mass index and lower adiponectinconcentration predict higher serum thromboxane B2 level in aspirin-treated patientswith type 2 diabetes: an observational study / A. Kaplon-Cieslicka, M. Postula, M.Rosiak // Cardiovasc Diabetol..
– 2014. – 13. – Р. 112.128. Kojuri, J. Dose-related effect of aspirin on laboratory-defined platelet aggregationand clinical outcome after coronary stenting / J. Kojuri, Y. Mahmoody, B.. ZangbarSabegh // Cardiovasc Ther. – 2010. – 28(3). – Р. 147-52.129. Krasopoulos, G.1. Aspirin "resistance" and risk of cardiovascular morbidity:systematic review and meta-analysis / G.1. Krasopoulos, S.J.
Brister, W.S. Beattieet al. // BMJ. – 2008. – 26;336(7637). – 195-98.130. Larsen, S.B. Determinants of reduced antiplatelet effect of aspirin in patients withstable coronary artery disease / S.B. Larsen, E.L. Grove, S.D. Kristensen et al. //PLoS One. – 2015.
– Vol. 10, № 5. – e0126767 (doi:10.1371/journal. pone.0126767).131. Li, J. Laboratory aspirin resistance and the risk of major adverse cardiovascularevents in patients with coronary heart disease on confirmed aspirin adherence / J. Li,M. Song, Z. Jian et. al. // J Atheroscler Thromb. –2014. – 21(3). – Р. 239-47.132. Liu, X.F. Prevalence of and risk factors for aspirin resistance in elderly patientswith coronary artery disease / X.F. Liu, J.
Cao, L. Fan et. al. // J Geriatr Cardiol. –2013. – 10(1). – Р. 21-27.133.Macchi, L. Aspirin resistance: definitions, mechanisms, prevalence, and clinicalsignificance / L. Macchi, N. Sorel, L. Christiaens // Curr Pharm Des. –2006. – 12(2).– Р. 251-58.134.McCoy, L.A. Association of Discharge Aspirin Dose With Outcomes After AcuteMyocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors:Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary129Syndrome (TRANSLATE-ACS) Study / L.A.
McCoy, Y. Xian, T.Y. Wang //Circulation. – 2015. – 132(3). – Р.174-81.135. Michelson, A.D. Aspirin Resistance: position paper of the Working Group onAspirin Resistance / A.D. Michelson, M. Cattaneo, J.W. Eikelboom // ThrombHaemost. – 2005.
– 3. – P. 1309-11.136. Miyata, S. Aspirin resistance / S. Miyata, T. Miyata, A. Kada et. al. // Brain Nerve.– 2008. – 60(11). – Р. 1357-1364.137. Modica, A. Platelet aggregation and aspirin non-responsiveness increase when anacute coronary syndrome is complicated by an infection / A. Modica, F. Karlsson, T.Mooe // J Thromb Haemost. – 2007. – 5(3) – Р. 507-11.138. Oh, M.S. Aspirin resistance is associated with increased stroke severity and infarctvolume / M.S. Oh, K.H. Yu, J.H. Lee et. al. // Neurology. – 2016.
– 86 (19). – Р.1808-17.139. Oh, J. Efficacy of aspirin and statins in primary prevention of cardiovascularmortality in uncomplicated hypertensive participants: a Korean national cohort study/J.Oh,C.J.Lee,S.HLee//JHypertens.–2017.–doi:10.1097/HJH.0000000000001279.140. Oliveira, D.C. Aspirin resistance: fact or fiction? / D.C. Oliveira, RF.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
